WAILEA, HAWAII (FRONTLINE MEDICAL NEWS) – Many atopic dermatitis patients with refractory disease may have also developed allergic contact dermatitis, according to Jonathan Silverberg, MD, of Northwestern University in Chicago.

Clinically, there is often overlap between AD and allergic contact dermatitis, said Dr. Silverberg , who was involved in the development of recent consensus guidelines on when to do patch testing in the setting of AD.

For many patients with severe disease, “sometimes when we patch test, we can find a relevant allergen for the patient to avoid, [and] within a few months, their disease just goes down a notch, gets much better, and really starts to respond to topical and more conservative approaches,” Dr. Silverberg said in a video interview at the Hawaii Dermatology Seminar provided by Global Academy for Medical Education/Skin Disease Education Foundation. Or patients may respond well to AD treatment on certain parts of the body, but there may be other areas that don’t respond as well, suggesting a possible component of allergic contact dermatitis, he added

The guidelines sought to sort out scenarios “where it makes sense to patch test” and to provide direction on best practices, noted Dr. Silverberg, who is director of the Northwestern Medicine Multidisciplinary Eczema Center, and director of the patch testing clinic, Northwestern Memorial Hospital, Chicago.

He disclosed relationships with companies including AbbVie, Anacor, Celgene, Chugai, GlaxoSmithKline, Lilly, MedImmune-AstraZeneca, Pfizer, Procter & Gamble, Puricore, and Regeneron-Sanofi.SDEF and this news organization are owned by the same parent company.


You May Also Like

Breastfeeding lowers later diabetes risk in women

FROM JAMA INTERNAL MEDICINE Breastfeeding may reduce a woman’s risk of developing diabetes, with ...

Additional D1 biopsy increased diagnostic yield for celiac disease

Among a large cohort of patients referred for endoscopy for suspected celiac disease as ...

Intraperitoneal chemo still underused for ovarian cancer

FROM JOURNAL OF CLINICAL ONCOLOGY Intraperitoneal chemotherapy provides a clear survival benefit in stage ...